Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Freissmuth, M; Waldhoer, M; Bofill-Cardona, E; Nanoff, C.
G protein antagonists.
TRENDS PHARMACOL SCI 1999 20: 237-245.
Doi: 10.1016/S0165-6147(99)01337-1
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Waldhoer Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Heterotrimeric G proteins couple membrane-bound heptahelical receptors to their cellular effector systems (ion channels or enzymes generating a second messenger). In current pharmacotherapy, the input to G protein-regulated signalling is typically manipulated by targeting the receptor with appropriate agonists or antagonists and, to a lesser extent, by altering second messenger levels, most notably by inhibiting phosphodiesterases that hydrolyse cyclic nucleotides. When stimulated, G proteins undergo a cycle of activation and deactivation in which the alpha-subunits and the betagamma-dimers sequentially expose binding sites for their reaction partners (receptors, guanine nucleotides and effectors, as well as regulatory proteins). These domains can be blocked by inhibitors and this produces effects that cannot be achieved by receptor antagonists. Here, the structural and mechanistic information on G protein antagonists is summarized and an outline of the arguments supporting the hypothesis that G proteins per se are also potential drug targets is provided.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antineoplastic Agents - pharmacology
- GTP-Binding Proteins - antagonists and inhibitors
- Humans - antagonists and inhibitors
- Protein Binding - drug effects
- Research Support, Non-U.S. Gov't - drug effects
- Signal Transduction - drug effects
- Suramin - pharmacology